These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19801101)

  • 1. Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
    Wachsberger P; Burd R; Ryan A; Daskalakis C; Dicker AP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):854-61. PubMed ID: 19801101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
    Chen J; Smith M; Kolinsky K; Adames V; Mehta N; Fritzky L; Rashed M; Wheeldon E; Linn M; Higgins B
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):651-9. PubMed ID: 16937104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
    Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
    Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
    Meyerhardt JA; Ancukiewicz M; Abrams TA; Schrag D; Enzinger PC; Chan JA; Kulke MH; Wolpin BM; Goldstein M; Blaszkowsky L; Zhu AX; Elliott M; Regan E; Jain RK; Duda DG
    PLoS One; 2012; 7(6):e38231. PubMed ID: 22701615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
    Brazelle WD; Shi W; Siemann DW
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):836-41. PubMed ID: 16751064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
    Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
    Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
    Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
    Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
    Williams KJ; Telfer BA; Shannon AM; Babur M; Stratford IJ; Wedge SR
    Mol Cancer Ther; 2007 Feb; 6(2):599-606. PubMed ID: 17308057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
    Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
    Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
    Ren W; Korchin B; Lahat G; Wei C; Bolshakov S; Nguyen T; Merritt W; Dicker A; Lazar A; Sood A; Pollock RE; Lev D
    Clin Cancer Res; 2008 Sep; 14(17):5466-75. PubMed ID: 18765538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.
    Tamura K; Takada M; Kawase I; Tada T; Kudoh S; Okishio K; Fukuoka M; Yamaoka N; Fujiwara Y; Yamakido M
    Jpn J Cancer Res; 1997 Feb; 88(2):218-23. PubMed ID: 9119752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
    Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
    Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.